Clicky

Monday, November 2, 2026

Earnings

Results and financial condition

Peoples Bancorp reports Q3 2026 results, declares dividend

Peoples Bancorp Inc. announces its Q3 2026 financial results, declaring a quarterly dividend of $0.42 per share as part of its commitment to shareholders.

CoastalSouth Bancshares Reports Strong Q3 Results

CoastalSouth Bancshares, Inc. announces positive third-quarter results, indicating growth and stability in the state commercial banking sector.

Chord Energy announces CEO transition amid Q3 results

Chord Energy Corp announces the appointment of Michael Lou as CEO following Daniel Brown's resignation, alongside preliminary Q3 financial results.

Citius Pharmaceuticals Reports 120% Growth in LYMPHIR Sales

Citius Pharmaceuticals announces a 120% increase in LYMPHIR sales, indicating strong demand and positioning in the oncology market.

The Hartford Reports Strong Q3 2026 Results, Boosts Dividends

The Hartford Insurance Group announces strong third-quarter results, including a 23% rise in net income and a 12% increase in dividends for shareholders.

Datavault AI Inc. Announces Non-Reliance on Financial Statements

Datavault AI Inc. reveals that its prior financial statements are unreliable due to accounting errors, raising concerns for investors and the tech sector.

City Holding Company Reports Record Earnings for Q3 2026

City Holding Company announces record Q3 2026 earnings with net income of $34.6 million and EPS of $2.43, showcasing strong growth in the banking sector.

Burke & Herbert Financial Services Reports Q3 Results, Dividend

Burke & Herbert Financial Services Corp. announces strong Q3 results with $36.2 million net income and declares $0.55 per share dividend.

Shore Bancshares Reports Third Quarter Earnings Decline

Shore Bancshares Inc. reports third-quarter earnings of $16.8 million, reflecting challenges in the national commercial banking sector.

Xtend AI Robotics announces preliminary revenue, new CEO

Xtend AI Robotics reports preliminary revenue of $24.5-$26.5 million and appoints Matt McGraw as CEO, signaling growth in the autonomous systems sector.

Bank of Hawaii reports solid Q3 results, boosts buyback program

Bank of Hawaii Corp announces Q3 earnings of $1.49 per share and increases share repurchase program by $200 million, reflecting strong financial performance.

LiveWire Group Announces CEO Resignation, Board Changes

LiveWire Group, Inc. announces CEO resignation and new board appointments as part of a strategic restructuring effort.

Medifast Reports Third Quarter Earnings Decline Amid Challenges

Medifast, Inc. faces a revenue drop in Q3 2026, driven by fewer active coaches and market pressures, as it aims for profitability in the next quarter.

Valion Bio Receives Acquisition Interest for Velocity Bioworks

Valion Bio, Inc. announces unsolicited acquisition interest in its Velocity Bioworks subsidiary, evaluating strategic options for growth and development.

ENB Financial Corp Reports Strong Q3 2026 Earnings Growth

ENB Financial Corp announces a 16.8% rise in Q3 net income, reflecting successful integration of Cecil Bancorp and robust loan growth.

Stewart Information Services reports Q3 2026 financial results

Stewart Information Services Corp reports Q3 2026 results, showing revenue growth but a decline in net income amid industry challenges.

Consumer Portfolio Services Reports Strong Q3 2026 Results

Consumer Portfolio Services, Inc. announces impressive Q3 results with significant growth in net income and loan origination, impacting the finance services sector.

Oak Valley Bancorp reports strong Q3 results with higher income

Oak Valley Bancorp announces increased net income and improved margins for Q3 2026, reflecting strong operational performance in the state commercial banking sector.

Eagle Bancorp Reports Q3 2026 Results, Declares Dividend

Eagle Bancorp, Inc. announces significant Q3 2026 results with increased net income and a cash dividend, reflecting strategic growth in the commercial banking sector.

Cognition Therapeutics Gains FDA Alignment for Phase 3 Trial

Cognition Therapeutics announces FDA alignment on its Phase 3 trial for zervimesine, a treatment for dementia with Lewy bodies.

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →